National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia ...
Consenso Delphi nacional sobre el manejo perioperatorio y localmente avanzado del Cancer de Pulmon de Celular no Pequeña en Colombia...
"Medicine can have extraordinary meaning. But it cannot substitute for being present in your own life."
In #APieceofMyMind, a psychiatrist and residency program director reflects on an unexpected #LungCancer diagnosis.
https://t.co/V3Tae6P6mU
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung cancer with clinical/biological heterogeneity. Management is largely extrapolated from other lung cancer paradigms. Check out a recent review on this challenging disease.
https://t.co/69gYL24Dkq
2025: Summary of Ttx for NSCLC in 3 slides
➕: IO is SoC in early stage
➖: multiple « me too » agents but cost of drugs is ⬆️ and access is ⬇️ worldwide
✏️: optimal Ttx duration with IO or TT
✏️: access to TT for rare 🧬altertions
✏️: role of ADCs?
We need more Academic trials!
We are thrilled to welcome internationally renowned cardiovascular surgeon Juan Pablo Umaña, M.D., to @UMiamiMedicine and UHealth as our new Chief of Cardiothoracic Surgery! ❤️
Dr. Umaña is a global leader in aortic and mitral valve repair, the founder of the Latin-American Cardiovascular Surgery Conference, and the visionary behind Latin America's most extensive heart valve repair program. His arrival marks a transformative moment for our cardiovascular care — bringing innovation, leadership, and a deep commitment to patient-centered excellence.
From training the next generation of surgeons to advancing minimally invasive techniques, Dr. Umaña is poised to lead us into a new era of care — for South Florida and beyond. 🙌 Learn more: https://t.co/wzfLoSLSpA
Advances in molecular pathology and therapy of non-small cell lung cancer
💫An exceptionally comprehensive review (72 pages 👀)
Algorithms👇
https://t.co/1bFwMu6sAp
#ASCO25@JuliaRotow@DanaFarber elegantly presents the case for #osimertinib Monotherapy over combination strategies (FLAURA2, MARIPOSA)
▶️ Reserving combination for higher risk pts
▶️ Maximixing each therapy in sequential approach
▶️ Shared decision w patients
@EGFRResisters
Preoperative chemoimmunotherapy followed by surgery and postoperative immunotherapy in lung cancer: limited compliance for all planned therapy #ASCO25 @OncoAlert